BMEA - Total Utang marang Modal Biomea Fusion Corp

Logo perusahaan publik Biomea Fusion, Inc. (BMEA)

Pharmaceutical developments by Biomea Fusion, Inc. (BMEA) target the treatment of prolonged metabolic dysfunctions. This price chart shows that Biomea Fusion, Inc. (BMEA) shares reflect a debt load of 0.07. The company is scaling the creation of covalent inhibitors for leukemia and diabetes therapy while undergoing FDA review. Revenue is expected to be generated from the sale of innovative insulin regeneration tablets, the cost of which will be covered by insurance companies.

BMEA: Total Utang marang Modal Biomea Fusion 04.07.2022 - 30.10.2026

Rincian analitis perusahaan Biomea Fusion, Inc.

- rega lan prakiraan konsensus rega:
Bagan rega Biomea Fusion|BMEA - Bagan tingkat prakiraan
- statistik kapitalisasi pasar:
Kapitalisasi pasar Biomea Fusion|BMEA - Nilai Dipunlarasaken Utang lan Kas
- indikator kapitalisasi buku:
Nilai Buku saben Saham Biomea Fusion|BMEA - Kapitalisasi Buku|Rasio Nilai Pasar marang Nilai Buku biomeafusion.com|BMEA - Nilai Agregat Aset
- indikator total utang lan likuiditas perusahaan:
Utang marang Ekuitas Biomea Fusion, Inc.|BMEA - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal Biomea Fusion, Inc.|BMEA - Gunggung utang perusahaan|Utang marang nilai buku Biomea Fusion|BMEA - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Biomea Fusion|Rasio cepet biomeafusion.com
- informasi bathi lan kelipatan valuasi:
BMEA - Penghasilan resik perusahaan
Analisis dhasar perusahaan:Biomea Fusion
Barang utama Biomea Fusion Corp

This ratio compares total debt obligations to equity, determining the level of financial leverage. It allows for an assessment of the business's dependence on borrowed funds and its overall stability. By analyzing the dynamics of the company's financial dependence, an investor identifies the balance between bankruptcy risk and growth rates. For Biomea Fusion, Inc. (BMEA), this is critical, as the costly logistics of metabolic drugs require stable financing. Optimal leverage ensures the seamless operation of certified supply chains.

Analisis pesaing Biomea Fusion, Inc.

Utang marang Ekuitas Ascendis Pharma|Madrigal Pharmaceuticals Inc - Utang Agregat marang Ekuitas|Total Utang marang Modal CORT|RYTM (Rhythm Corp) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal AKRO (Akero Therapeutics)|Total Utang marang Modal metsera.com MTSR|MLTX - Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi CRNX (Crinetics Pharmaceuticals, Inc.)|NewAmsterdam Pharma N.V. (NAMS) - Utang marang Ekuitas|Rasio Total Utang marang Ekuitas Soleno Therapeutics Corp|FOLD (Amicus Therapeutics) - Total Utang marang Modal|Total Utang marang Modal 89bio.com|Rasio Total Utang marang Ekuitas AGIO (Agios Pharmaceuticals, Inc.)|GPCR (Structure Therapeutics Inc) - Rasio Kabeh Utang marang Dana Pribadi|Utang marang Ekuitas MiMedx Group MDXG|RZLT - Rasio Total Utang marang Ekuitas|Lexicon Pharmaceuticals - Total Utang marang Modal|Utang marang Modal mbxbio.com|ALT (Altimmune) - Rasio Total Utang marang Ekuitas|AARD: Utang Agregat marang Modal|SGMT (Sagimet) - Total Utang marang Modal|Total Utang marang Modal BioAge Labs, Inc|Total Utang marang Modal QNCX|Utang marang Ekuitas GUTS (fractyl.com)|Utang marang Ekuitas vTv Therapeutics VTVT|Agape ATP Corp (ATPC) - Utang marang Modal|PLUR - Utang marang Ekuitas|SYBX: Utang marang Ekuitas|LPCN: Total Utang marang Modal|MTNB - Koefisien Total Utang marang Modal|Utang marang Ekuitas Spruce Biosciences, Inc.|Galecto Inc (GLTO) - Koefisien Total Utang marang Modal|Utang marang Ekuitas Carmell Corp (CTCX)|Rasio Total Utang marang Ekuitas Lumos Therapeutics LUMO|Total Utang marang Modal ONVO (Organovo Holdings, Inc.)|radiuspharm.com - Utang marang Ekuitas